MedTrace Logo

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-14

No results posted yet for this study

Summary

The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.

Conditions

  • Breast Carcinoma

Interventions

DRUG

Carboplatin

Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses

DRUG

Paclitaxel

80 mg/m\^2 IV over 1-3 hours weekly for 12 doses

DRUG

Bevacizumab

10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses

DRUG

Trastuzumab

4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses

DRUG

Pertuzumab

840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Rita Mehta, MD · University of California, Irvine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2023-11-30
Completion
2036-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02436993 on ClinicalTrials.gov